Tanshinone-induced ERs suppresses IGFII activation to alleviate Ang II-mediated cardiac hypertrophy

References

• Distefano G, Sciacca P. Molecular pathogenesis of myocardial remodeling and new potential therapeutic targets in chronic heart failure. Ital J Pediatr. 2012;38:41.
   PubMed Web of Science ®Google Scholar
• Zhou H, Yuan Y, Liu Y, et al. Icariin attenuates angiotensin II-induced hypertrophy and apoptosis in H9c2 cardiomyocytes by inhibiting reactive oxygen species-dependent JNK and p38 pathways. Exp Ther Med. 2014;7:1116–1122.
   PubMed Web of Science ®Google Scholar
• van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest. 2013;123:37–45.
   PubMed Web of Science ®Google Scholar
• Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol. 2012;60:2465–2472.
   PubMed Web of Science ®Google Scholar
• Chang MH, Kuo WW, Chen RJ, et al. IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells. J Mol Endocrinol. 2008;41:65–74.
   PubMed Web of Science ®Google Scholar
• Chu CH, Tzang BS, Chen LM, et al. IGF-II/mannose-6-phosphate receptor signaling induced cell hypertrophy and atrial natriuretic peptide/BNP expression via Galphaq interaction and protein kinase C-alpha/CaMKII activation in H9c2 cardiomyoblast cells. J Endocrinol. 2008;197:381–390.
   PubMed Web of Science ®Google Scholar
• Huang CY, Kuo WW, Yeh YL, et al. ANG II promotes IGF-IIR expression and cardiomyocyte apoptosis by inhibiting HSF1 via JNK activation and SIRT1 degradation. Cell Death Differ. 2014;21:1262–1274.
   PubMed Web of Science ®Google Scholar
• Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004;286:R233–R249.
   PubMed Web of Science ®Google Scholar
• Dubey RK, Imthurn B, Zacharia LC, et al. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension. 2004;44:789–795.
   PubMed Web of Science ®Google Scholar
• Dubey RK, Jackson EK. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol. 2001;280:F365–F388.
   PubMed Web of Science ®Google Scholar
• Wu CH, Liu JY, Wu JP, et al. 17beta-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats. Life Sci. 2005;78:347–356.
   PubMed Web of Science ®Google Scholar
• Liu CJ, Lo JF, Kuo CH, et al. Akt mediates 17beta-estradiol and/or estrogen receptor-alpha inhibition of LPS-induced tumor necresis factor-alpha expression and myocardial cell apoptosis by suppressing the JNK1/2-NFkappaB pathway. J Cell Mol Med. 2009;13:3655–3667.
   PubMed Web of Science ®Google Scholar
• Weng YS, Kuo WW, Lin YM, et al. Danshen mediates through estrogen receptors to activate Akt and inhibit apoptosis effect of Leu27IGF-II-induced IGF-II receptor signaling activation in cardiomyoblasts. Food Chem Toxicol. 2013;56:28–39.
   PubMed Web of Science ®Google Scholar
• Huang CY, Kuo WW, Kuo CH, et al. Protective effect of Danggui (Radix Angelicae Sinensis) on angiotensin II-induced apoptosis in H9c2 cardiomyoblast cells. BMC Complement Altern Med. 2014;14:358.
   PubMed Web of Science ®Google Scholar
• Gao S, Liu Z, Li H, et al. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 2012;220:3–10.
   PubMed Web of Science ®Google Scholar
• Wang P, Wu X, Bao Y, et al. Tanshinone IIA prevents cardiac remodeling through attenuating NAD (P)H oxidase-derived reactive oxygen species production in hypertensive rats. Die Pharmazie. 2011;66:517–524.
   PubMed Web of Science ®Google Scholar
• Tan X, Li J, Wang X, et al. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway. Int J Biol Sci. 2011;7:383–389.
   PubMed Web of Science ®Google Scholar
• Feng J, Li SS, Liang QS. [Effects of Tanshinone II A on the myocardial apoptosis and the miR-133 levels in rats with heart failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chin J Integr Tradition West Med]. 2012;32:930–933.
   PubMedGoogle Scholar
• Qiao Z, Ma J, Liu H. Evaluation of the antioxidant potential of Salvia miltiorrhiza ethanol extract in a rat model of ischemia-reperfusion injury. Molecules. 2011;16:10002–10012.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang L, Chu W, et al. Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes. Cell Physiol Biochem. 2010;26:991–998.
   PubMed Web of Science ®Google Scholar
• Yang P, Jia YH, Li J, et al. Study of anti-myocardial cell oxidative stress action and effect of tanshinone IIA on prohibitin expression. J Tradition Chin Med. [Chung i Tsa Chih Ying Wen Pan]. 2010;30:259–264.
   PubMed Web of Science ®Google Scholar
• Chan P, Liu JC, Lin LJ, et al. Tanshinone IIA inhibits angiotensin II-induced cell proliferation in rat cardiac fibroblasts. Am J Chin Med. 2011;39:381–394.
   PubMed Web of Science ®Google Scholar
• Pang H, Han B, Yu T, et al. The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy. PLoS One. 2014;9:e92216.
   PubMed Web of Science ®Google Scholar
• Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA. 2006;103:17985–17990.
   PubMed Web of Science ®Google Scholar
• Smeets PJ, Teunissen BE, Planavila A, et al. Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta. J Biol Chem. 2008;283:29109–29118.
   PubMed Web of Science ®Google Scholar
• Qi G, Jia L, Li Y, et al. Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. Cardiovasc Toxicol. 2011;11:157–167.
   PubMed Web of Science ®Google Scholar
• Sopel MJ, Rosin NL, Lee TD, et al. Myocardial fibrosis in response to Angiotensin II is preceded by the recruitment of mesenchymal progenitor cells. Lab Invest. 2011;91:565–578.
   PubMed Web of Science ®Google Scholar
• Li YG, Song L, Liu M, et al. Advancement in analysis of Salviae miltiorrhizae Radix et Rhizoma (Danshen). J Chromatogr A. 2009;1216:1941–1953.
   PubMed Web of Science ®Google Scholar
• Wen XD, Wang CZ, Yu C, et al. Salvia miltiorrhiza (dan shen) significantly ameliorates colon inflammation in dextran sulfate sodium induced colitis. Am J Chin Med. 2013;41:1097–1108.
   PubMed Web of Science ®Google Scholar
• Lin C, Wang L, Wang H, et al. Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways. J Cell Biochem. 2013;114:2061–2070.
   PubMed Web of Science ®Google Scholar
• Tang FT, Cao Y, Wang TQ, et al. Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol. 2011;650:275–284.
   PubMed Web of Science ®Google Scholar
• Sun DD, Wang HC, Wang XB, et al. Tanshinone IIA: a new activator of human cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels. Eur J Pharmacol. 2008;590:317–321.
   PubMed Web of Science ®Google Scholar
• Wenden A, Yang Y, Chai L, et al. Salvia miltiorrhiza induces VEGF expression and regulates expression of VEGF receptors in osteoblastic cells. Phytother Res. 2014;28:673–677.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45:1345–1359.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu Y, Li Y, et al. Tanshinone IIA improves miR-133 expression through MAPK ERK1/2 pathway in hypoxic cardiac myocytes. Cell Physiol Biochem. 2012;30:843–852.
   PubMed Web of Science ®Google Scholar
• Wei B, You MG, Ling JJ, et al. Regulation of antioxidant system, lipids and fatty acid β-oxidation contributes to the cardioprotective effect of sodium tanshinone IIA sulphonate in isoproterenol-induced myocardial infarction in rats. Atherosclerosis. 2013;230:148–156.
   PubMed Web of Science ®Google Scholar
• Shang Q, Wang H, Li S, et al. The effect of sodium tanshinone IIA sulfate and simvastatin on elevated serum levels of inflammatory markers in patients with coronary heart disease: a study protocol for a randomized controlled trial. eCAM. 2013;2013:756519.
   Google Scholar
• Kagiyama S, Eguchi S, Frank GD, et al. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation. 2002;106:909–912.
   PubMed Web of Science ®Google Scholar
• Wang KC, Tosh DN, Zhang S, et al. IGF-2R-Galphaq signaling and cardiac hypertrophy in the low-birth-weight lamb. Am J Physiol Regul Integr Comp Physiol. 2015;308:R627–R635.
   PubMed Web of Science ®Google Scholar
• Gruber CJ, Tschugguel W, Schneeberger C, et al. Production and actions of estrogens. N Engl J Med. 2002;346:340–352.
   PubMed Web of Science ®Google Scholar
• Li X, Huang J, Yi P, et al. Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol. 2004;24:7681–7694.
   PubMed Web of Science ®Google Scholar
• Weng YS, Wang HF, Pai PY, et al. Tanshinone IIA prevents Leu27IGF-II-induced cardiomyocyte hypertrophy mediated by estrogen receptor and subsequent Akt activation. Am J Chin Med. 2015;43:1567–1591.
   PubMed Web of Science ®Google Scholar
• Gao J, Yang G, Pi R, et al. Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Translat Res J Labor Clin Med. 2008;151:79–87.
   Google Scholar
• Hong HJ, Liu JC, Chen PY, et al. Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway. Int J Cardiol. 2012;157:174–179.
   PubMed Web of Science ®Google Scholar
• Duerrschmid C, Trial J, Wang Y, et al. Tumor necrosis factor: a mechanistic link between angiotensin-II-induced cardiac inflammation and fibrosis. Circ Heart Fail. 2015;8:352–361.
   PubMed Web of Science ®Google Scholar
• Qi GM, Jia LX, Li YL, et al. Adiponectin suppresses angiotensin II-induced inflammation and cardiac fibrosis through activation of macrophage autophagy. Endocrinology. 2014;155:2254–2265.
   PubMed Web of Science ®Google Scholar
• Wang M, Tsai BM, Reiger KM, et al. 17-beta-Estradiol decreases p38 MAPK-mediated myocardial inflammation and dysfunction following acute ischemia. J Mol Cell Cardiol. 2006;40:205–212.
   PubMed Web of Science ®Google Scholar
• Xing D, Feng W, Miller AP, et al. Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am J Physiol Heart Circulat Physiol. 2007;292:H2607–H2612.
   PubMed Web of Science ®Google Scholar
• Lee SD, Chu CH, Huang EJ, et al. Roles of insulin-like growth factor II in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation. Am J Physiology. Endocrinol Metabol. 2006;291:E306–E314.
   Web of Science ®Google Scholar
• Kuo WW, Liu CJ, Chen LM, et al. Cardiomyoblast apoptosis induced by insulin-like growth factor (IGF)-I resistance is IGF-II dependent and synergistically enhanced by angiotensin II. Apoptosis Int J Programm Cell Death. 2006;11:1075–1089.
   PubMed Web of Science ®Google Scholar
• Pedram A, Razandi M, Lubahn D, et al. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. Endocrinology. 2008;149:3361–3369.
   PubMed Web of Science ®Google Scholar
• Pelzer T, Jazbutyte V, Hu K, et al. The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc Res. 2005;67:604–612.
   PubMed Web of Science ®Google Scholar